主线行情“造神”！公募半年考：指数军团霸榜，黑马基金经理业绩狂飙86%

Core Insights - The A-share market in the first half of 2025 is experiencing a volatile pattern influenced by policy and fundamentals, with public fund managers showing significant performance [3][4] - The top fund managers are predominantly managing index funds, with a notable increase in the scale of the HuShen 300 ETF [5][6] Group 1: Fund Management Performance - As of July 1, 2025, the top ten fund managers by management scale are all index fund managers, with Liu Jun from Huatai Baichuan Fund leading at 4120.1 billion yuan [3][6] - Zhang Wei from Huitianfu Fund emerged as a standout performer, with his fund achieving an 86.48% return, significantly outperforming the market [4][21] - The HuShen 300 ETF has seen substantial growth, with its scale surpassing 4000 billion yuan, although it faced a slight decline in late June [7][10] Group 2: Index Fund Dynamics - The HuShen 300 ETF, managed by Liu Jun, has a scale of 3738.6 billion yuan and a one-year performance increase of 46.4% [7][10] - The performance of major index funds is consistent, with returns around 46% to 47% over the past year, reflecting the nature of index funds to track their benchmark closely [14][15] - The top ten weighted stocks in the HuShen 300 index include major companies like Kweichow Moutai and Ningde Times, which collectively account for over 20% of the index [16][17] Group 3: Emerging Fund Managers - New-generation fund managers are showing impressive results, with Zhang Wei achieving a 47.9% return in the first half of 2025 [21][22] - Zhang Lu from Yongying Fund also performed well, with a return of 33.88%, indicating a trend of strong performance among emerging managers [21][22] - The recent performance of these managers suggests a shift in the competitive landscape of fund management, with a focus on sectors like pharmaceuticals and advanced manufacturing [29][36] Group 4: Sector Trends and Opportunities - The pharmaceutical sector is highlighted as a key area for investment, with significant returns driven by the rebound in innovative drug stocks [27][29] - The focus on high-dividend strategies and industry leaders within the HuShen 300 index is expected to drive future growth in ETF scales [17][18] - The performance of funds in the manufacturing sector, particularly those focusing on humanoid robots, has shown remarkable returns, indicating a potential trend for future investments [46][50]